Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.

View in: PubMed

subject areas

Adult
Aged
Aminoglycosides
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Core Binding Factors
Cytarabine
Disease-Free Survival
Female
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Survival Rate
Vidarabine

authors with profiles

HAGOP M KANTARJIAN
RAJYALAKSHMI LUTHRA
JORGE E CORTES
FARHAD RAVANDI-KASHANI
GUILLERMO GARCIA-MANERO
ELIAS JOSEPH JABBOUR
GAUTAM BORTHAKUR
TAPAN MAHENDRA KADIA